RYMAN HEALTHCARE LIMITED (RYM)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

RYM - RYMAN HEALTHCARE LIMITED

FNArena Sector : Aged Care & Seniors

Year End: March

GICS Industry Group : Health Care Equipment & Services

Debt/EBITDA: -45.38

Index:

LAST PRICE	CHANGE +/-	CHANGE %	VOLUME
$2.36 11 Feb 2026	0.020 OPEN $2.36	0.85% HIGH $2.36	4,727 LOW $2.31

LAST PRICE

CHANGE +/-

CHANGE %

VOLUME

$2.36

11 Feb
2026

0.020

OPEN

$2.36

0.85%

HIGH

$2.36

4,727

LOW

$2.31

OTHER COMPANIES IN THE SAME SECTOR
EGH . INA . LIC . OCA . REG .

FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

HISTORICAL DATA ARE ALL IN AUD

Copyright © 2026 FactSet UK Limited. All rights reserved

Title	2020	2021	2022	2023	2024	2025
EPS Basic	xxx	xxx	xxx	xxx	xxx	-56.0
DPS All	xxx	xxx	xxx	xxx	xxx	0.0
Sales/Revenue	xxx	xxx	xxx	xxx	xxx	649.8 M
Book Value Per Share	xxx	xxx	xxx	xxx	xxx	381.7
Net Operating Cash Flow	xxx	xxx	xxx	xxx	xxx	326.4 M
Net Profit Margin	xxx	xxx	xxx	xxx	xxx	-61.20 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title	2020	2021	2022	2023	2024	2025
Return on Capital Employed	xxx	xxx	xxx	xxx	xxx	-10.04 %
Return on Invested Capital	xxx	xxx	xxx	xxx	xxx	-6.73 %
Return on Assets	xxx	xxx	xxx	xxx	xxx	-3.46 %
Return on Equity	xxx	xxx	xxx	xxx	xxx	-10.04 %
Return on Total Capital	xxx	xxx	xxx	xxx	xxx	-1.32 %
Free Cash Flow ex dividends	xxx	xxx	xxx	xxx	xxx	231.8 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title	2020	2021	2022	2023	2024	2025
Short-Term Debt	xxx	xxx	xxx	xxx	xxx	0 M
Long Term Debt	xxx	xxx	xxx	xxx	xxx	1,541 M
Total Debt	xxx	xxx	xxx	xxx	xxx	1,541 M
Goodwill - Gross	xxx	xxx	xxx	xxx	xxx	-
Cash & Equivalents - Generic	xxx	xxx	xxx	xxx	xxx	16 M
Price To Book Value	xxx	xxx	xxx	xxx	xxx	0.66

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title	2020	2021	2022	2023	2024	2025
Capex	xxx	xxx	xxx	xxx	xxx	97.4 M
Capex % of Sales	xxx	xxx	xxx	xxx	xxx	14.99 %
Cost of Goods Sold	xxx	xxx	xxx	xxx	xxx	728 M
Selling, General & Admin. Exp & Other	xxx	xxx	xxx	xxx	xxx	0 M
Research & Development	xxx	xxx	xxx	xxx	xxx	-
Investments - Total	xxx	xxx	xxx	xxx	xxx	9,828 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
EXTRA COVERAGE

EXPERT VIEWS

Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

BROKER	DATE	RATING	RECOMMENDATION	TARGET PRICE	% TO REACH TARGET	COMMENTARY

Access Stockbroker Research History >

EXTRA COVERAGE

Display All Commentary

No. Of Recommendations

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER	DATE	RATING	RECOMMENDATION	TARGET PRICE	% TO REACH TARGET	COMMENTARY
Jarden	09/02/2026	3	Neutral	-	-	In the wake of the investor briefing from Ryman Healthcare, Jarden notes significant debt and development losses have dominated the investment case for the past three years. A transition is now occurring in which yield will become the focus for investors, with asset growth providing valuation support albeit as a second consideration to the 14,500 unit and bed asset base. The broker believes investors will need to be patient, although there is an attractive growth trajectory envisaged for the next 10-15 years. Neutral rating. Targets edges up to NZ$2.96 from NZ$2.94. FORECAST Jarden forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -3.77 cents. Jarden forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -3.95 cents.

BROKER

DATE

RATING

RECOMMENDATION

TARGET PRICE

% TO REACH TARGET

COMMENTARY

Jarden

09/02/2026

Neutral

In the wake of the investor briefing from Ryman Healthcare, Jarden notes significant debt and development losses have dominated the investment case for the past three years.

A transition is now occurring in which yield will become the focus for investors, with asset growth providing valuation support albeit as a second consideration to the 14,500 unit and bed asset base.

The broker believes investors will need to be patient, although there is an attractive growth trajectory envisaged for the next 10-15 years. Neutral rating. Targets edges up to NZ$2.96 from NZ$2.94.

FORECAST
Jarden forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -3.77 cents.
Jarden forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -3.95 cents.

Access Extra Coverage Research History >

RYM STOCK CHART

FNArena News on RYM

1	Australian Broker Call Extra Edition – Feb 09, 2026 Feb 09 2026 - Daily Market Reports

2	Rudi’s View: Pre-February Top Picks & Favourites Jan 15 2026 - Rudi's View

Latest Aged Care & Seniors News

1	SMSFundamentals: Should You Sell Your Home To Buy Your Nursing ‘Home’? Apr 24 2025 - SMSFundamentals

2	SMSFundamentals: Living Longer? Get Ready To Pay The Price! Jan 31 2025 - SMSFundamentals

3	Treasure Chest: Regis Healthcare Sep 18 2024 - Treasure Chest

4	Treasure Chest: Lifestyle Communities En Vogue Mar 19 2024 - Treasure Chest

5	Lifestyle Communities Enjoying Strong Demand Feb 21 2022 - Small Caps

6	Aged Care Sector: Poised Mar 16 2021 - Australia

7	Pressure Grows On Estia Health Dec 10 2019 - Australia

8	Aveo Group Now A Binary Proposition Jun 26 2019 - Australia

9	Aged Care Moves Into The RC Spotlight Sep 20 2018 - Australia

10	Regis Healthcare In Strong Shape For FY19 Sep 04 2018 - Australia

Get 2 Weeks free trial

Sign Up

Member Login

RYMAN HEALTHCARE LIMITED (RYM)
Share Price Analysis and Chart